SCHEMBL4336499

SCHEMBL4336499

CN1CCN(c2cc(N3CCN(c4ccccc4Cl)CC3)c(F)cc2C=NNC(N)=S)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.47
MAPT P10636 5/20 0.42
GAA P10253 3/20 0.42
ATM Q13315 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
POLB P06746 2/20 0.41
KMT2A Q03164 1/20 0.41
MCL1 Q07820 2/20 0.41
MYC P01106 1/20 0.40
ALDH1A1 P00352 4/20 0.40
HTT P42858 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
ALOX12 P18054 2/20 0.40
KDM4E B2RXH2 2/20 0.40
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CSF1R P07333 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
DRD2 P14416 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4336498 1.00 MAOB (0.47) MAOBMAPTGAAATMNPSR1
SCHEMBL4338942 0.93 DRD2 (0.50) MAOBMAPTGAAATMNPSR1
SCHEMBL4338940 0.93 DRD2 (0.50) MAOBMAPTGAAATMNPSR1
SCHEMBL4344374 0.92 MAOB (0.52) MAOBMAPTGAAATMNPSR1
SCHEMBL4344377 0.92 MAOB (0.52) MAOBMAPTGAAATMNPSR1
SCHEMBL4332877 0.90 MAOB (0.47) MAOBMAPTGAAATMNPSR1
SCHEMBL4332872 0.90 MAOB (0.47) MAOBMAPTGAAATMNPSR1
SCHEMBL13887165 0.89 MAOB (0.48) MAOBMAPTGAAATMNPSR1
SCHEMBL4327844 0.87 MAOB (0.45) MAOBMAPTGAAATMNPSR1
SCHEMBL4329890 0.87 MAPT (0.52) MAOBMAPTGAANPSR1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 2762/4885MAPT 3619/4885GAA 2113/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAOB 3093/4885MAPT 3876/4885GAA 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.